Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy

Experimental and Therapeutic Medicine

Volumn 6, Issue 1, 2013, Pages 109-114

  Xie, Wanzhuo ^a   Zhou, De ^a   Hu, Keyue ^a   Xiao, Xibin ^b   Huang, Weijia ^a   He, Jinsong ^a   Shi, Jimin ^a   Luo, Yi ^a   Zhang, Jie ^a   Lin, Maofang ^a   Cai, Zhen ^a   Huang, He ^a   Ye, Xiujin ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Diffuse large B cell lymphoma; Hepatitis B virus; Lamivudine; Rituximab; Serum hepatitis B virus DNA load

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DIAMMONIUM GLYCYRRHIZINATE; DOXORUBICIN; GLUTATHIONE; GLYCYRRHIZIC ACID; HEPATITIS B SURFACE ANTIGEN; INORGANIC COMPOUND; LACTATE DEHYDROGENASE; LAMIVUDINE; PHOSPHATIDYLCHOLINE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; VIRUS DNA;

ADULT; AGED; ANN ARBOR STAGING; BONE MARROW BIOPSY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; STAGING; VIRUS LOAD; VIRUS REACTIVATION;

EID: 84878204678     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1079     Document Type: Review

References (23)

1. Ganem D and Prince AM: Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350: 1118-1129, 2004.
2. Lok AS and McMahon BJ: Chronic hepatitis B. Hepatology 45: 507-539, 2007.
3. Lok AS, Lai CL, Wu PC, Wong VC, Yeoh EK and Lin HJ: Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 126: 492-499, 1987.
4. Sun Z, Ming L, Zhu X and Lu J: Prevention and control of hepatitis B in China. J Med Virol 67: 447-450, 2002.
5. Kuniyoshi M, Nakamuta M, Sakai H, et al: Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphoma. J Gastroenterol Hepatol 16: 215-219, 2001.
6. Marcucci F, Mele A, Spada E, et al: High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 91: 554-557, 2006.
7. Cucuianu A, Patiu M, Duma M, et al: Hepatitis B and C virus infection in Romanian non-Hodgkin's lymphoma patients. Br J Haematol 107: 353-356, 1999.
8. Vento S, Cainelli F and Longhi MS: Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 3: 333-340, 2002.
9. Skrabs C, Müller C, Agis H, Mannhalter C and Jäger U: Treatment of HBV-carrying lymphoma patients with rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia 16: 1884-1886, 2002.
10. Liang RH, Lok AS, Lai CL, Chan TK, Todd D and Chiu EK: Hepatitis B infection in patients with lymphomas. Hematol Oncol 8: 261-270, 1990.
11. Rehermann B, Ferrari C, Pasquinelli C and Chisari FV: The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2: 1104-1108, 1996.
12. Yuki N, Nagaoka T, Yamashiro M, et al: Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology37: 1172-1179, 2003.
13. Yeo W and Johnson PJ: Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43: 209-220, 2006.
14. Xunrong L, Yan AW, Liang R and Lau GK: Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev Med Virol 11: 287-299, 2001.
15. Kitano K, Kobayashi H, Hanamura M, et al: Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol 77: 255-258, 2006.
16. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242, 2002.
17. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24: 3121-3127, 2006.
18. Dai MS, Chao TY, Kao WY, Shyu RY and Liu TM: Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 83: 769-774, 2004.
19. Westhoff TH, Jochimsen F, Schmittel A, et al: Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 102: 1930, 2003.
20. Hsu C, Hsiung CA, Su IJ, et al: A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 47: 844-853, 2008.
21. Conconi A, Zucca E, Roggero E, et al: Prognostic models for diffuse large B-cell lymphoma. Hematol Oncol 18: 61-73, 2000.
22. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association: The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Liu Xing Bing Xue Za Zhi 32: 405-415, 2011 (In Chinese).
23. Wang F, Xu RH, Luo HY, et al: Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer 8: 115, 2008.